Evolving Role of Bone Health and Radiopharmaceuticals in Prostate Cancer Care

The fourth segment of this roundtable features an in-depth discussion on recent advancements in prostate cancer treatment, focusing on the impact of landmark trials such as ARASENS, ARANOTE, and PEACE-3. The panel explores the complexities of implementing combination therapies like darolutamide with chemotherapy and enzalutamide with radium-223. The conversation also highlights the challenges of adapting clinical trial findings to real-world practice, the significance of bone health in metastatic prostate cancer, and the evolving role of radiopharmaceuticals like radium-223 and lutetium.